Timothy Ehrlich, chair of Gunderson Dettmer LLP’s life sciences practice group, has a strong record representing life sciences companies across their lifecycle, specializing in biotechnology, pharmaceuticals, and healthcare IT, advising on financings, strategic alliances, and M&A. Notable matters include guiding Remix Therapeutics in its $60m financing and billion-dollar collaboration with Roche, and Kelonia Therapeutics’ $800m partnership with Xyphos Biosciences.
L'éditorial du Legal 500
- Profil
- Réseaux sociaux
Distinctions
Boston Elite
Clients clés
- Remix Therapeutics, Inc.
- Kelonia Therapeutics, Inc.
- BrainChild Bio, Inc.
- Moonwalk Biosciences, Inc.
- QurAlis Corporation
- Be Biopharma
- MBrace Therapeutics
- DEM BioPharma
- Carbon Biosciences
- Kernal Bio
- Muna Therapeutics
- Photys Therapeutics
- Praxis Precision Medicines
Points forts
Advised Remix Therapeutics, Inc., a biotech company, in its $60m financing and a high-value collaboration with Roche, which included a $30m upfront payment and potential milestone payments exceeding $1bn.
Advised Kelonia Therapeutics, Inc., in its $800m research collaboration and licensing agreement with Xyphos Biosciences, a subsidiary of Astellas Pharma. The agreement includes $40m upfront, $35m for additional options, milestone payments, R&D funding, and tiered royalties on future sales.
Represented Be Biopharma in its $82m financing, backed by Bristol Myers Squibb, Takeda Ventures, and top venture firms.